SERA PROGNOSTICS, INC.

Sera Prognostics announced the resignation of Jeffrey T. Elliott from its Board of Directors, effective June 4, 2026, the date of the Annual Stockholders Meeting. His departure was not due to any disagreement with the company, with Mr. Elliott citing increasing demands on his time. Following his resignation, the Board's size was reduced to seven directors. The company is actively seeking highly qualified candidates for new board appointments to maintain strong corporate governance.

Sera Prognostics reported a net loss of $(8.4) million for the first quarter of 2026, a slight increase from $(8.2) million in the prior year's quarter, despite a decrease in revenue to $14 thousand. The net loss per share improved to $(0.17). The company also established a new at-the-market sales agreement to potentially raise up to $40.0 million, and noted that enrollment in its PRIME study was stopped in December 2023 due to efficacy.

Sera Prognostics Inc. announced its first quarter 2026 financial results, reporting revenue of $14,000 and a net loss of $8.4 million. Despite the financial decline, the company successfully extended its cash runway through 2029 by redirecting investments from clinical activities to commercialization and rightsizing its operating model. Key business highlights include the publication of the landmark PRIME Randomized Trial, expansion of its European evidence base, launch of a third partnership program, and active discussions with 13 payers.

SERA PROGNOSTICS, INC. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026. Shareholders will vote on the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor. The company also highlighted significant progress in 2025 and early 2026, including the publication of the landmark PRIME Study demonstrating the PreTRM ® test's effectiveness, expanded commercial engagement, and a successful $57.5 million equity financing that extends its cash runway through 2028.

Sera Prognostics, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, virtually. The company highlighted significant progress in 2025 and early 2026, including the publication of the landmark PRIME Study demonstrating the PreTRM® test's effectiveness in reducing preterm births and newborn complications. Commercial engagement expanded across target states, and a successful $57.5 million equity financing extended the cash runway through 2028. The meeting agenda includes the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor.